Results 11 to 20 of about 3,675 (177)

Sensing of HIV-1 by TLR8 activates human T cells and reverses latency [PDF]

Nature Communications, 2020
Manipulation of Toll-like receptors (TLRs) affects HIV-1 infection and latency reversal. Here, the authors show that HIV-1 is endocytosed and recognized by TLR8 in human primary CD4+T cells and that TLR8 stimulation induces an inflammatory response that ...
Hany Zekaria Meås, Markus Haug, Marianne Sandvold Beckwith, Claire Louet, Liv Ryan, Zhenyi Hu, Johannes Landskron, Svein Arne Nordbø, Kjetil Taskén, Hang Yin, Jan Kristian Damås, Trude Helen Flo   +11 more
doaj   +6 more sources

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention

Viruses, 2023
Antiretroviral therapy (ART) has dramatically improved the prognosis for people living with HIV-1, but a cure remains elusive. The largest barrier to a cure is the presence of a long-lived latent reservoir that persists within a heterogenous mix of cell ...
Catherine A. Lewis, David M. Margolis, Edward P. Browne   +2 more
doaj   +3 more sources

Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents. [PDF]

PLoS Computational Biology, 2018
Eradicating HIV-1 infection is difficult because of the reservoir of latently infected cells that gets established soon after infection, remains hidden from antiretroviral drugs and host immune responses, and retains the capacity to reignite infection ...
Vipul Gupta, Narendra M Dixit
doaj   +4 more sources

Modulation of IRF7-driven transcription as a strategy to control HIV-1 latency [PDF]

Frontiers in Immunology
BackgroundThe persistence of latent HIV-1 reservoirs remains a major barrier to achieving a cure for HIV. While latency-reversing agents (LRAs) have been extensively studied, latency-promoting agents (LPAs) offer a complementary strategy to silence viral
Ifeanyi Jude Ezeonwumelu, Ifeanyi Jude Ezeonwumelu, Edurne Garcia-Vidal, Edurne Garcia-Vidal, Eudald Felip, Eudald Felip, Eudald Felip, Sara Cabrero-de las Heras, Sara Cabrero-de las Heras, Bonaventura Clotet, Bonaventura Clotet, Roger Badia, Roger Badia, Ester Ballana, Ester Ballana, Ester Ballana, Eva Riveira-Muñoz, Eva Riveira-Muñoz, Maria Nevot, Maria Nevot   +19 more
doaj   +2 more sources

Identification of celastrol as a novel HIV-1 latency reversal agent by an image-based screen. [PDF]

PLoS One, 2021
Although current antiretroviral therapies (ART) are successful in controlling HIV-1 infection, a stable viral reservoir reactivates when ART is discontinued. Consequently, there is a major research effort to develop approaches to disrupt the latent viral reservoir and enhance the immune system’s ability to clear HIV-1.
Liu H, Hu PW, Dubrulle J, Stossi F, Nikolai BC, Mancini MA, Rice AP.   +6 more
europepmc   +6 more sources

Shocking HIV-1 with immunomodulatory latency reversing agents [PDF]

Seminars in Immunology, 2021
The "shock-and-kill" strategy is one of the most explored HIV-1 cure approaches to eliminate latent virus. This strategy is based on HIV-1 reactivation using latency reversing agents (LRAs) to reactivate latent proviruses (the "shock" phase) and to induce subsequent elimination of the reactivated cells by immune responses or virus-induced cytopathic ...
Anna Kula-Pacurar, Anthony Rodari, Gilles Darcis, Carine Van Lint   +3 more
openaire   +4 more sources

Molecular chaperones at the host–virus interface: heat shock protein roles in HIV-1 and emerging insights for HIV-2 and dual infection [PDF]

Frontiers in Cellular and Infection Microbiology
Heat shock proteins (HSPs) are essential molecular chaperones involved in protein folding, cellular stress responses, and homeostasis. Recent studies reveal their critical and dual roles in the human immunodeficiency virus (HIV) life cycle, both ...
Sabastine Eugene Arthur, Sabastine Eugene Arthur, Kirk Klogo, Emmanuel Kobina Mensah, Maame Ama Pentsiwa Cudjoe, Maame Ama Pentsiwa Cudjoe, Adomia Baaba Mensah, Nyamekye Amoabeng Ankrah, Catherine Laaripuoh Omosule, Catherine Laaripuoh Omosule, Evelyn Yayra Bonney, George Boateng Kyei, George Boateng Kyei, George Boateng Kyei, George Boateng Kyei   +14 more
doaj   +2 more sources

Lithium attenuates HIV-1 latency reversal in an autophagy-independent way. [PDF]

iScience
The major barrier to eradicate HIV-1 is its persistence in latently infected cells. Inducing deep latency to prevent HIV-1 reactivation in the absence of combined antiretroviral therapy (cART) remains a primary goal. Here, we evaluated the repurposing of lithium as an HIV-1 latency-promoting drug (LPA).
Abdalla AL, Guajardo-Contreras G, Chau BA, Niu M, Murooka T, Mouland AJ.   +5 more
europepmc   +3 more sources

The Current Status of Latency Reversing Agents for HIV-1 Remission [PDF]

Annual Review of Virology, 2021
Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1 (HIV-1) replication but is not curative because cART interruption almost invariably leads to a rapid rebound of viremia due to the persistence of stable HIV-1-infected cellular reservoirs.
Rodari, Anthony, Darcis, Gilles, Van Lint, Carine   +2 more
openaire   +3 more sources

Cleavage and Polyadenylation Specificity Factor 6 Is Required for Efficient HIV-1 Latency Reversal. [PDF]

mBio, 2021
CPSF6 is a cellular factor that regulates cleavage and polyadenylation of mRNAs and participates in HIV-1 infection by facilitating targeting of preintegration complexes to the chromatin. Our observations reveal a second role of CPSF6 in the HIV-1 life cycle that involves regulation of viral transcription through controlling the stability of protein ...
Zheng Y, Schubert HL, Singh PK, Martins LJ, Engelman AN, D'Orso I, Hill CP, Planelles V.   +7 more
europepmc   +4 more sources